Trials / Completed
CompletedNCT01652729
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 365 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exenatide once weekly suspension | |
| DRUG | Sitagliptin | |
| DRUG | Placebo | Placebo oral capsule once daily |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2012-07-30
- Last updated
- 2015-08-20
- Results posted
- 2015-04-23
Locations
60 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01652729. Inclusion in this directory is not an endorsement.